Viridian Therapeutics Stock In The News
| VRDN Stock | USD 20.08 0.65 3.35% |
Our overall analysis of Viridian Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Viridian Therapeutics. The specific impact of Viridian Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Viridian Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Viridian Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Viridian Therapeutics Backtesting and Viridian Therapeutics Hype Analysis. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.
Viridian |
Viridian Therapeutics Today Top News and Investor Outlook
Viridian Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Viridian and other traded companies coverage with news coverage. We help investors stay connected with Viridian headlines for the 30th of January to make an informed investment decision based on correlating the impacts of news items on Viridian Stock performance. Please note that trading solely based on the Viridian Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
Viridian Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Viridian earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Viridian Therapeutics that are available to investors today. That information is available publicly through Viridian media outlets and privately through word of mouth or via Viridian internal channels. However, regardless of the origin, that massive amount of Viridian data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Viridian Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Viridian Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Viridian Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Viridian Therapeutics alpha.
Viridian Largest EPS Surprises
Earnings surprises can significantly impact Viridian Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.89 | -1.02 | -0.13 | 14 | ||
2022-11-14 | 2022-09-30 | -1.02 | -0.86 | 0.16 | 15 | ||
2022-08-15 | 2022-06-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2023-11-13 | 2023-09-30 | -1.27 | -1.09 | 0.18 | 14 | ||
2021-11-04 | 2021-09-30 | -1.47 | -1.25 | 0.22 | 14 | ||
2024-05-08 | 2024-03-31 | -1.1 | -0.79 | 0.31 | 28 |
Viridian Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Viridian Therapeutics Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
28th of January 2025
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Di... at news.google.com
26th of December 2024
Disposition of 15656 shares by Lara Meisner of Viridian Therapeutics at 28.12 subject to R... at MacroaxisInsider
19th of December 2024
This C3.ai Analyst Turns Bearish Here Are Top 5 Downgrades For Thursday at benzinga.com
16th of December 2024
Viridian Therapeutics Announces Positive Phase 3 Results for Veligrotug in Treating Thyroi... at gurufocus.com
13th of December 2024
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 1... at businesswire.com
6th of December 2024
Viridian Therapeutics SWOT analysis biotech stock poised for growth in TED market at investing.com
4th of December 2024
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 at businesswire.com
2nd of December 2024
Acquisition by Kiselak Tomas of 20000 shares of Viridian Therapeutics at 27.67 subject to ... at MacroaxisInsider
25th of November 2024
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note Here Are Top 5 Initiat... at benzinga.com
7th of November 2024
MannKind Matches Q3 Earnings Estimates at zacks.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Viridian Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Viridian Therapeutics' short interest history, or implied volatility extrapolated from Viridian Therapeutics options trading.
Check out Viridian Therapeutics Backtesting and Viridian Therapeutics Hype Analysis. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share | Quarterly Revenue Growth 0.194 | Return On Assets | Return On Equity |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.